Marker Therapeutics, Inc. MRKR
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -34.03%
- 1 year
- +2.39%
- Market cap
- 16.39M
- Revenue (ttm)
- 3.73M
- Profit margin
- -278.22%
- EPS (ttm)
- -0.42
- Shares out
- 8.92M
- Forward P/E
- -2.34
- YTD return
- -34.03%
- 1-year return
- +2.39%
- Volume
- 94.61K
- Avg volume
- 111.66K
- Open
- 0.9051
- Previous close
- 0.9011
- Day's range
- 0.8928 – 0.9991
- 52-week range
- 0.84 – 2.46
- Beta
- 1.49
- Analysts
- Strong Buy
- Price target
- 19.00 (+1833.1%)
- Earnings date
- Mar 27, 2024
2Y -2.5459 (-72.33%)
Key statistics
- Enterprise value
- 19.59M
- PEG ratio
- 0.00
- Price / sales
- 8.19
- Price / book
- 2.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 53.30%
- Free cash flow
- -7.40M
- Total cash
- 7.80M
- Total debt
- 0
- Return on equity
- -71.74%
- Short % of float
- 1.09%
- 50-day average
- 3.71
- 200-day average
- 3.97
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 27, 2024
Expected Mar 27, 2024. Consensus EPS estimate -0.28.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.26 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.25 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.27 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.34 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.47 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 30, 2024 | Ladenburg Thalmann | init | — | Buy |
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- markertherapeutics.com
News
Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer 
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer 
12 Health Care Stocks Moving In Friday's Intraday Session 
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy 
New Strong Buy Stocks for October 16th 
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker 
5 Small Drug Stocks to Invest in Amid a Biotech Comeback 
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
Your note
Sign in to keep a note on MRKR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 12.01% | 1,071,428 | 3.66M | Sep 29, 2024 |
| Aisling Capital Management LP | 3.52% | 314,286 | 1.07M | Sep 29, 2024 |
| Vanguard Group Inc | 2.72% | 243,122 | 831.48K | Sep 29, 2024 |
| AR Asset Management, Inc. | 0.83% | 73,700 | 252.05K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.80% | 71,561 | 244.74K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.45% | 39,750 | 135.94K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.72% | 153,473 | 524.88K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.98% | 87,137 | 298.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 39,946 | 136.62K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.19% | 16,579 | 56.70K | Oct 30, 2024 |
| DFA U.S. Small Cap Series | 0.18% | 15,900 | 54.38K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 12,811 | 43.81K | Oct 30, 2024 |